Skip to main content
. 2000 Jun 20;97(14):8039–8044. doi: 10.1073/pnas.140123497

Figure 1.

Figure 1

Proportion of UL97 single-site mutant within the population after the initiation of GCV therapy. Therapy lasts for 21 days and the fitness difference (s; Eq. 1) of mutant to wild type after cessation of therapy is the same as the fitness gain of mutant over wild type during therapy (5.6%). Three different starting concentrations of mutant within the population are modeled (0.015%, 0.15%, and 1.5%).